A Practice Note summarizing policy and regulatory changes since 2020 that primarily affect companies based in or operating in the People's Republic of China (China). In recent years, both the US government and the Chinese government have increased their focus on and scrutiny of China-based issuers that are listed in or conduct capital markets transactions in the US. This Note provides an overview of the US's policy and regulatory responses, which have primarily focused on modifying rules and recommendations related to disclosure, due diligence, and accounting and audit rules. Counsel should consider these recent developments when advising or performing due diligence on China-based issuers.